Cargando…
Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report
INTRODUCTION: Reversible cerebral vasoconstriction syndrome presents with thunderclap headaches accompanied by mild neurologic deficits and is characterized by multifocal narrowing of the cerebral arteries that resolves over days to weeks. This syndrome may be idiopathic or occur in special contexts...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260136/ https://www.ncbi.nlm.nih.gov/pubmed/22074635 http://dx.doi.org/10.1186/1752-1947-5-548 |
_version_ | 1782221442288451584 |
---|---|
author | Cvetanovich, Gregory L Ramakrishnan, Pankajavalli Klein, Joshua P Rao, Vikram R Ropper, Allan H |
author_facet | Cvetanovich, Gregory L Ramakrishnan, Pankajavalli Klein, Joshua P Rao, Vikram R Ropper, Allan H |
author_sort | Cvetanovich, Gregory L |
collection | PubMed |
description | INTRODUCTION: Reversible cerebral vasoconstriction syndrome presents with thunderclap headaches accompanied by mild neurologic deficits and is characterized by multifocal narrowing of the cerebral arteries that resolves over days to weeks. This syndrome may be idiopathic or occur in special contexts, most often involving adrenergic or serotonergic overactivity. To the best of our knowledge, reversible cerebral vasoconstriction syndrome has not previously been reported in association with Hydroxycut use in the literature. CASE PRESENTATION: We report the case of a 65-year-old Caucasian woman on longstanding citalopram who developed reversible cerebral vasoconstriction syndrome two weeks after beginning to take the weight-loss supplement Hydroxycut. CONCLUSION: There are sparse data about the safety of herbal supplements such as Hydroxycut, even though the Food and Drug Administration has banned some herbal ingredients, such as ephedra, that were in this preparation in the past. This case highlights the importance of considering herbal supplements and potential drug interactions in the genesis of otherwise unexplained reversible cerebral vasoconstriction syndrome. |
format | Online Article Text |
id | pubmed-3260136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32601362012-01-18 Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report Cvetanovich, Gregory L Ramakrishnan, Pankajavalli Klein, Joshua P Rao, Vikram R Ropper, Allan H J Med Case Reports Case Report INTRODUCTION: Reversible cerebral vasoconstriction syndrome presents with thunderclap headaches accompanied by mild neurologic deficits and is characterized by multifocal narrowing of the cerebral arteries that resolves over days to weeks. This syndrome may be idiopathic or occur in special contexts, most often involving adrenergic or serotonergic overactivity. To the best of our knowledge, reversible cerebral vasoconstriction syndrome has not previously been reported in association with Hydroxycut use in the literature. CASE PRESENTATION: We report the case of a 65-year-old Caucasian woman on longstanding citalopram who developed reversible cerebral vasoconstriction syndrome two weeks after beginning to take the weight-loss supplement Hydroxycut. CONCLUSION: There are sparse data about the safety of herbal supplements such as Hydroxycut, even though the Food and Drug Administration has banned some herbal ingredients, such as ephedra, that were in this preparation in the past. This case highlights the importance of considering herbal supplements and potential drug interactions in the genesis of otherwise unexplained reversible cerebral vasoconstriction syndrome. BioMed Central 2011-11-10 /pmc/articles/PMC3260136/ /pubmed/22074635 http://dx.doi.org/10.1186/1752-1947-5-548 Text en Copyright ©2011 Cvetanovich et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Cvetanovich, Gregory L Ramakrishnan, Pankajavalli Klein, Joshua P Rao, Vikram R Ropper, Allan H Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report |
title | Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report |
title_full | Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report |
title_fullStr | Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report |
title_full_unstemmed | Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report |
title_short | Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report |
title_sort | reversible cerebral vasoconstriction syndrome in a patient taking citalopram and hydroxycut: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260136/ https://www.ncbi.nlm.nih.gov/pubmed/22074635 http://dx.doi.org/10.1186/1752-1947-5-548 |
work_keys_str_mv | AT cvetanovichgregoryl reversiblecerebralvasoconstrictionsyndromeinapatienttakingcitalopramandhydroxycutacasereport AT ramakrishnanpankajavalli reversiblecerebralvasoconstrictionsyndromeinapatienttakingcitalopramandhydroxycutacasereport AT kleinjoshuap reversiblecerebralvasoconstrictionsyndromeinapatienttakingcitalopramandhydroxycutacasereport AT raovikramr reversiblecerebralvasoconstrictionsyndromeinapatienttakingcitalopramandhydroxycutacasereport AT ropperallanh reversiblecerebralvasoconstrictionsyndromeinapatienttakingcitalopramandhydroxycutacasereport |